Ensuring Compliance with FDA QMSR Standards
FDA QMSR Inspection Model
The FDA QMSR Inspection Model describes how FDA investigators evaluate medical device manufacturers under Compliance Program 7382.850. Inspections focus on a manufacturer’s quality management system, manufacturing operations, supplier controls, and postmarket regulatory obligations across the total product lifecycle. Understanding how FDA conducts inspections helps manufacturers prepare their quality systems, documentation, and personnel for regulatory review. Many organizations conduct mock FDA inspections or seek FDA consulting support to evaluate inspection readiness before regulators arrive.
How FDA Investigators Inspect Medical Device Manufacturers
FDA investigators inspect medical device manufacturers using the inspection framework described in Compliance Program 7382.850 under the Quality Management System Regulation (QMSR). During an FDA inspection, investigators review the manufacturer’s quality management system, manufacturing operations, supplier controls, and regulatory compliance activities across the total product lifecycle.
Investigators examine procedures, records, and operational practices to determine whether the manufacturer maintains adequate control over device design, production, and quality system implementation. Understanding how FDA investigators inspect manufacturers is critical for maintaining inspection readiness. Many organizations engage FDA consulting support or conduct a mock FDA inspection to assess how their quality systems and manufacturing operations would perform during an actual regulatory inspection.
Inspection Methodology Under CP 7382.850
FDA Compliance Program 7382.850 establishes the inspection methodology used by FDA investigators when inspecting medical device manufacturers under the Quality Management System Regulation (QMSR). The program provides guidance to FDA investigators and compliance staff for conducting regulatory inspections and evaluating medical device manufacturing operations and quality management systems.
Under this compliance program, FDA inspections follow a risk-based approach that evaluates a manufacturer’s quality management system across key operational areas, including management responsibility, production controls, supplier management, and postmarket regulatory obligations. Investigators review procedures, records, and operational practices to determine whether manufacturers maintain adequate control over device design, manufacturing processes, and quality system implementation.
Because this inspection methodology emphasizes risk, process interaction, and operational implementation, many manufacturers seek FDA consulting support or conduct a mock FDA inspection to evaluate inspection readiness under the same inspection framework used by FDA investigators.
Risk-Based Inspection Process
The inspection methodology described in CP 7382.850 directs FDA investigators to apply a risk-based approach when reviewing medical device manufacturers. Investigators evaluate the potential impact of manufacturing processes, device risks, and quality system performance when determining which records and procedures to review during an inspection.
Rather than simply verifying whether procedures exist, investigators assess whether quality system processes are effectively implemented and supported by adequate documentation. For example, investigators may review CAPA investigations, manufacturing deviations, supplier controls, and complaint handling activities to determine whether quality issues are properly identified and resolved. This risk-based inspection framework reflects the broader objective of ensuring that medical devices remain safe and effective throughout the total product lifecycle.
Inspection Models Used by FDA Investigators
CP 7382.850 describes different inspection models used by FDA investigators depending on the type of inspection assignment. For example, PMA preapproval inspections typically follow Inspection Model 2, while PMA postmarket inspections often follow Inspection Model 1.
These inspection models guide investigators on which quality system areas and regulatory requirements should receive inspection coverage during specific types of inspections. The scope and depth of inspection coverage may vary depending on the regulatory assignment, product risk, and compliance history of the manufacturer.
Understanding how these inspection models are applied can help manufacturers better prepare their quality systems and documentation for FDA inspection.
Why This Matters for Mock FDA Inspection
A mock FDA inspection is most effective when it follows the same inspection methodology described in CP 7382.850. FDA consulting services that replicate the actual inspection framework used by FDA investigators allow manufacturers to evaluate how their quality management system and manufacturing operations would perform during a real FDA inspection.
By simulating the inspection approach used by regulators, a mock FDA inspection can identify potential compliance gaps, documentation weaknesses, and operational risks before FDA investigators arrive.
How PMA and Postmarket Requirements Are Reviewed During FDA Inspections
FDA inspections conducted under Compliance Program 7382.850 often include evaluation of both premarket and postmarket regulatory obligations. In addition to reviewing quality system controls, FDA investigators may examine how manufacturers meet regulatory requirements associated with Premarket Approval (PMA), Medical Device Reporting (MDR), corrections and removals, device tracking, and other postmarket regulatory responsibilities.
For PMA-regulated devices, FDA investigators conduct inspections to determine whether the manufacturer has properly implemented manufacturing processes, validation activities, and quality system controls necessary to support the approved device. Investigators also review whether commitments made during the PMA approval process have been implemented and maintained.
In practice, this means FDA inspections may combine review of manufacturing operations, quality system implementation, and postmarket regulatory reporting systems within the same inspection. Manufacturers often engage FDA consulting services or conduct a mock FDA inspection to ensure that both premarket and postmarket regulatory requirements are properly implemented and supported by adequate documentation.
PMA Preapproval Inspections
For PMA preapproval inspections, investigators focus on the specific device that is the subject of the PMA application. Investigators review manufacturing processes, validation activities, and quality system procedures associated with that device to determine whether the manufacturer is capable of producing the device in compliance with regulatory requirements.
For sterile devices, FDA investigators may also examine sterilization validation and sterile barrier system controls to ensure that the manufacturing process can consistently produce safe and effective products.
PMA Postmarket Inspections
After a device has received PMA approval, FDA investigators may conduct postmarket inspections to verify that the manufacturer continues to comply with regulatory requirements and that commitments made during the PMA approval process have been fulfilled.
These inspections may also include review of postmarket data such as complaints, recalls, adverse event reports, and design or manufacturing changes affecting the approved device.
Integration of PMA and Postmarket Reporting Requirements
CP 7382.850 instructs investigators to review other applicable FDA requirements during inspections when appropriate. These may include Medical Device Reporting (21 CFR Part 803), corrections and removals reporting (21 CFR Part 806), medical device tracking requirements (21 CFR Part 821), and Unique Device Identification requirements.
Because these regulatory requirements are often evaluated during the same FDA inspection, manufacturers should ensure that complaint handling systems, MDR reporting procedures, recall processes, and traceability controls are properly implemented and documented.
A mock FDA inspection conducted as part of FDA consulting services can evaluate these postmarket systems and help manufacturers confirm that regulatory reporting procedures are functioning as required.
Difference Between QSIT and QMSR
Many medical device manufacturers are familiar with the Quality System Inspection Technique (QSIT), which historically guided FDA inspections under the previous quality system framework. The implementation of the Quality Management System Regulation (QMSR) and Compliance Program 7382.850 represents an evolution in how FDA investigators inspect medical device manufacturers.
QSIT organized inspections around defined subsystems such as management controls, CAPA, design controls, and production and process controls. In contrast, the QMSR inspection model places greater emphasis on evaluating the quality management system as an integrated set of processes across manufacturing operations, supplier management, and postmarket regulatory activities.
Under CP 7382.850, FDA investigators apply a risk-based inspection approach that considers product risks, manufacturing processes, and quality system performance across the total product lifecycle. Because this inspection framework emphasizes risk management and process interaction, many manufacturers conduct a mock FDA inspection or seek FDA consulting support to evaluate inspection readiness under the new QMSR inspection model.
QSIT Subsystem-Based Inspection Structure
Under QSIT, inspections were commonly organized around several key subsystems of the quality system. Investigators typically focused on reviewing documentation and procedures within those defined subsystems.
While this approach helped standardize inspections, it sometimes encouraged manufacturers to prepare for inspections primarily by subsystem rather than by evaluating how quality system processes interact across the organization.
QMSR Risk-Based Inspection Framework
The QMSR inspection model described in CP 7382.850 emphasizes evaluation of the manufacturer’s quality management system as an integrated set of processes rather than isolated subsystems. Investigators are directed to apply critical thinking and risk-based decision making when determining which areas of the quality system require inspection coverage.
This approach allows investigators to focus on areas where manufacturing practices, quality system performance, or postmarket information may present a higher risk to patients or users.
Implications for FDA Inspection Readiness
Manufacturers preparing for FDA inspections should recognize that inspection expectations continue to evolve under the QMSR inspection framework. Quality systems must demonstrate effective implementation across management oversight, manufacturing operations, supplier controls, and postmarket regulatory reporting.
For this reason, many organizations conduct mock FDA inspections or engage FDA consulting services to evaluate inspection readiness using the same risk-based inspection methodology applied by FDA investigators.
How FDA Consulting Helps Manufacturers Prepare for Inspections
Preparing for an FDA inspection requires more than maintaining written procedures. FDA investigators examine how quality management systems are implemented across manufacturing operations, supplier oversight, documentation practices, and postmarket regulatory reporting. Many manufacturers seek FDA consulting support to better understand how investigators inspect medical device manufacturers under Compliance Program 7382.850 and the QMSR inspection framework.
FDA consulting services help organizations evaluate their quality systems using the same inspection approach applied by FDA investigators. Independent regulatory experts review quality system documentation, manufacturing records, CAPA investigations, complaint handling processes, and supplier controls to determine whether regulatory requirements are properly implemented.
Because FDA inspections are risk-based and focused on real operational practices, manufacturers often conduct a mock FDA inspection as part of FDA consulting support. These simulated inspections help identify compliance gaps, strengthen inspection readiness, and prepare personnel for FDA investigator interactions before a regulatory inspection occurs.
Mock FDA Inspection as a Consulting Tool
A mock FDA inspection is one of the most effective FDA consulting tools for evaluating inspection readiness. The exercise simulates how FDA investigators inspect manufacturing facilities, review quality system documentation, and interview personnel. By conducting a mock FDA inspection, manufacturers can evaluate their preparedness under the QMSR inspection framework and address potential compliance risks before an FDA inspection occurs.
How We Conduct a Mock FDA Inspection
A mock FDA inspection simulates how FDA investigators inspect medical device manufacturers under the QMSR inspection framework. Our mock inspections follow the same general structure used during regulatory inspections to evaluate inspection readiness and identify potential compliance risks.
Opening Meeting and Inspection Scope
The mock inspection begins with an opening meeting similar to an FDA inspection. The purpose, scope, and inspection approach are explained to management and quality leadership. Initial documents and procedures related to the quality management system are requested for review.
Inspection of Quality Systems and Manufacturing Operations
The mock inspection focuses on the manufacturer’s quality management system and manufacturing operations. This includes review of procedures, records, CAPA investigations, production controls, supplier oversight, complaint handling, and other critical quality system elements.
Inspection Closeout and Observations
At the conclusion of the mock inspection, findings and observations are discussed with company leadership. Potential compliance gaps, documentation weaknesses, and quality system risks are identified so the organization can address them before an FDA inspection occurs.
Quality System Areas Reviewed During FDA Inspections
During an FDA inspection, investigators review the manufacturer’s quality management system to determine whether processes are properly established, implemented, and maintained. Inspections focus on how quality system controls are applied across manufacturing operations, documentation practices, and management oversight. Understanding these quality system areas is critical for inspection readiness and is often evaluated during a mock FDA inspection conducted as part of FDA consulting support.
Management Responsibility and Quality System Oversight
FDA investigators evaluate whether company management maintains effective oversight of the quality management system. This includes review of management review activities, quality policies, organizational responsibilities, and the authority of the quality unit. Investigators assess whether leadership ensures adequate resources, appropriate quality system implementation, and timely resolution of quality issues.
Corrective and Preventive Action (CAPA)
The CAPA system is one of the most critical areas reviewed during FDA inspections. Investigators examine how the manufacturer identifies quality problems, investigates root causes, and implements corrective and preventive actions. FDA investigators often review CAPA records to determine whether investigations are thorough, properly documented, and effective in preventing recurrence of quality issues.
Production and Process Controls
These controls ensure that manufacturing processes are consistent and produce products that meet specifications. They include process validation and monitoring.
Manufacturing and Process Controls
FDA inspections also focus on how manufacturers control production processes to ensure devices consistently meet specifications. Investigators review production procedures, equipment controls, manufacturing records, and documentation practices to determine whether manufacturing activities are properly planned and monitored.
Inspection and Testing
Inspection and testing are critical for verifying that products meet quality standards and specifications before they are released to the market.
Nonconforming Product
Procedures for controlling nonconforming products ensure that such products are identified, documented, and prevented from reaching customers.
Document Controls
Document controls ensure that all quality system documents are current, accessible, and properly maintained. This is essential for traceability and accountability.
Management's Role in Quality Oversight
The Importance of Management Responsibility Under CP 7382.850
Under Compliance Program 7382.850, FDA investigators assess whether management maintains effective control over the quality management system. Management is responsible for ensuring that quality policies are established, resources are available, and quality system procedures are properly implemented throughout the organization.
Investigators review management review activities, internal communication of quality objectives, and oversight of quality system performance. Effective management responsibility demonstrates that leadership is actively engaged in maintaining regulatory compliance and supporting a culture of quality across manufacturing operations.
Manufacturing Operations and Process Controls
During an FDA inspection, investigators closely examine manufacturing operations and process controls to determine whether medical devices are consistently produced according to approved specifications and quality system requirements. Investigators review production procedures, equipment controls, process validation records, environmental controls, and manufacturing documentation to verify that the manufacturer maintains adequate control over device production. Weaknesses in manufacturing controls are one of the most common causes of FDA inspection observations.
For this reason, manufacturing operations are a critical focus during a mock FDA inspection conducted as part of FDA consulting services. A simulated inspection allows manufacturers to evaluate how production processes, validation activities, and manufacturing records would be reviewed by FDA investigators. Identifying gaps in manufacturing controls before an FDA inspection helps organizations strengthen compliance and improve overall inspection readiness.
Production and Service Provision
During an FDA inspection, investigators closely examine manufacturing operations and process controls to determine whether medical devices are consistently produced according to approved specifications and quality system requirements. Investigators review production procedures, equipment controls, process validation records, environmental controls, and manufacturing documentation to verify that the manufacturer maintains adequate control over device production. Weaknesses in manufacturing controls are one of the most common causes of FDA inspection observations.
For this reason, manufacturing operations are a critical focus during a mock FDA inspection conducted as part of FDA consulting services. A simulated inspection allows manufacturers to evaluate how production processes, validation activities, and manufacturing records would be reviewed by FDA investigators. Identifying gaps in manufacturing controls before an FDA inspection helps organizations strengthen compliance and improve overall inspection readiness.
Process Validation and Sterilization Controls
For manufacturing processes where results cannot be fully verified through inspection or testing, FDA investigators evaluate whether the manufacturer has properly validated the process. This includes review of validation protocols, validation reports, and ongoing monitoring activities to ensure the process consistently produces devices that meet specifications. For sterile medical devices, investigators also examine sterilization validation, sterile barrier systems, and environmental controls. Process validation and sterilization controls are often key areas reviewed during a mock FDA inspection to determine whether validation documentation and implementation meet regulatory expectations.
Product Identification and Traceability
FDA investigators also examine how manufacturers identify and track products throughout manufacturing and distribution. Identification and traceability systems allow manufacturers to determine which products were produced under specific manufacturing conditions and to locate affected devices if quality issues occur. During an FDA inspection, investigators review labeling controls, lot identification systems, production records, and traceability documentation. Mock FDA inspections conducted through FDA consulting services often evaluate these systems to confirm that manufacturers can quickly identify and trace products when regulatory or safety concerns arise.
ISO 13485:2016 — Clause 7.5.8
— Identification
Requires manufacturers to establish procedures for identifying products during all stages of receipt, production, installation, and servicing to prevent mix-ups.
ISO 13485:2016 — Clause 7.5.9
— Traceability
Requires traceability procedures for certain devices so that components, production lots, and distribution records can be traced when necessary to protect public health.
Supplier and Outsourcing Controls
During an FDA inspection, investigators evaluate how manufacturers control suppliers, contractors, and outsourced activities that affect device quality. Medical device manufacturers remain responsible for ensuring that purchased components, materials, and outsourced manufacturing processes meet specified requirements. FDA investigators review supplier qualification procedures, purchasing controls, supplier monitoring activities, and documentation supporting supplier performance. Weak supplier oversight can lead to significant compliance concerns during inspections. For this reason, supplier and outsourcing controls are frequently evaluated during a mock FDA inspection conducted as part of FDA consulting support to identify potential risks before an FDA inspection occurs.
Purchasing Controls and Supplier Qualification
Monitoring Outsourced Manufacturing Activities
FDA investigators review how manufacturers establish and maintain procedures for selecting, evaluating, and approving suppliers. Purchasing controls ensure that purchased materials, components, and services conform to specified requirements. During an FDA inspection, investigators typically review supplier qualification records, supplier evaluations, purchasing agreements, and documentation defining quality requirements for suppliers. Manufacturers must demonstrate that suppliers are capable of consistently providing materials or services that meet device specifications and regulatory requirements.
When manufacturing activities are outsourced to contract manufacturers or external service providers, the device manufacturer remains responsible for ensuring compliance with quality system requirements. FDA investigators evaluate how manufacturers monitor outsourced processes, including review of supplier performance, quality agreements, and oversight of contract manufacturing activities. Effective monitoring helps ensure that outsourced production and services remain under adequate quality control. Mock FDA inspections often evaluate outsourcing controls to determine whether manufacturers maintain sufficient oversight of external manufacturing partners.
Partner with CIRG for Postmarket Surveillance and Regulatory Compliance
Postmarket Surveillance and Regulatory Reporting
Postmarket surveillance and regulatory reporting are critical areas reviewed during an FDA inspection of medical device manufacturers. After devices are distributed to the market, manufacturers must maintain systems to monitor product performance, investigate complaints, and report certain events to the FDA when required by regulation. FDA investigators examine complaint handling procedures, adverse event investigations, and regulatory reporting processes to determine whether manufacturers properly identify and address potential safety concerns.
These areas are frequently evaluated during a mock FDA inspection conducted as part of FDA consulting services. Independent review helps manufacturers determine whether complaint investigations, reporting procedures, and postmarket monitoring systems meet regulatory expectations and support FDA inspection readiness.
Reference 21 CFR Part 803 — Medical Device Reporting
Medical Device Reporting (MDR)
Medical Device Reporting (MDR) requires manufacturers to identify, investigate, and report certain device-related adverse events to the FDA. During an FDA inspection, investigators review complaint files, adverse event investigations, and MDR submissions to determine whether reportable events have been properly identified and reported within required timelines. Investigators also evaluate procedures used to determine reportability and document decision-making.
FDA consulting and mock FDA inspection exercises often include review of MDR procedures and complaint investigations to verify that manufacturers can demonstrate compliance with regulatory reporting requirements.
Reference 21 CFR Part 806 — Reports of Corrections and Removals
Corrections and Removals
Manufacturers must maintain procedures for managing product corrections and removals when device issues may present a risk to health or violate regulatory requirements. Corrections and removals may include field corrections, device recalls, or other actions taken to address product problems.
During an FDA inspection, investigators review investigation records, internal decision-making processes, and notifications submitted to the FDA when required. As part of FDA consulting services, a mock FDA inspection can evaluate whether correction and removal procedures are properly implemented and whether manufacturers understand when regulatory reporting obligations apply.
Medical Device Tracking
Certain medical devices require tracking systems that allow manufacturers to locate devices after distribution. Device tracking systems help manufacturers identify affected products and notify patients or healthcare providers when safety concerns arise.
Reference
21 CFR Part 821 — Medical Device Tracking
During an FDA inspection, investigators review device tracking procedures and distribution records to determine whether manufacturers can trace devices throughout the supply chain. FDA consulting services and mock FDA inspections frequently evaluate these systems to ensure manufacturers maintain adequate traceability and tracking capabilities.
Why Manufacturers Conduct Mock FDA Inspections
Many medical device manufacturers conduct a mock FDA inspection to evaluate how their quality management system and manufacturing operations would perform during an actual FDA inspection. A mock FDA inspection simulates the inspection approach used by FDA investigators and helps organizations identify potential compliance gaps before regulators arrive. These exercises allow manufacturers to review procedures, documentation, and operational practices from the perspective of an FDA investigator.
Mock FDA inspections are often conducted as part of FDA consulting services to help organizations strengthen inspection readiness and improve quality system oversight. By identifying weaknesses in advance, manufacturers can address potential regulatory concerns and better prepare their teams for an FDA inspection.
Identifying Quality System Gaps Before FDA Arrives
A mock FDA inspection allows manufacturers to evaluate whether their quality management system is properly implemented and supported by adequate documentation. During the review, areas such as CAPA investigations, supplier controls, manufacturing records, complaint handling, and regulatory reporting may be examined to identify potential weaknesses. Identifying quality system gaps early allows organizations to correct deficiencies and strengthen compliance before an FDA inspection occurs.
Preparing Personnel for FDA Investigator Interviews
FDA inspections often involve direct interaction between investigators and company personnel. During these discussions, investigators may ask questions about procedures, quality system activities, and manufacturing operations. A mock FDA inspection helps prepare employees for these interactions by simulating investigator interviews and document requests. Preparing personnel in advance helps ensure that employees understand inspection procedures and can confidently respond to investigator questions.
Independent FDA Consulting Perspective
A mock FDA inspection conducted by experienced FDA consulting professionals provides an independent assessment of a manufacturer’s inspection readiness. Former FDA investigators, compliance officers, and regulatory reviewers understand how inspections are conducted and what investigators typically examine during facility inspections. This independent perspective helps manufacturers evaluate their quality systems and implement improvements that support long-term regulatory compliance and FDA inspection readiness.
FDA Consulting Services for Inspection Readiness
Mock FDA Inspections
Conduct comprehensive mock inspections to identify and rectify compliance gaps before the actual FDA visit.
Personnel Training Programs
Prepare your team for FDA interviews with tailored training sessions led by experienced consultants.
Compliance Documentation Review
Ensure all your documentation meets FDA standards through detailed reviews and feedback.
Regulatory Strategy Development
Develop robust regulatory strategies to navigate complex FDA requirements effectively.
FDA Consulting for Inspection Readiness
Maintaining continuous FDA inspection readiness requires a strong quality management system, effective regulatory oversight, and a clear understanding of how FDA investigators conduct inspections. FDA consulting services help medical device manufacturers evaluate their inspection readiness by reviewing quality system implementation, manufacturing controls, and regulatory compliance activities. Through regulatory advisory support and mock FDA inspections, manufacturers can identify potential compliance gaps and strengthen their quality systems before an FDA inspection occurs. Independent FDA consulting provides valuable insight into how investigators review documentation, evaluate procedures, and assess manufacturing operations during regulatory inspections.
Former FDA Investigators and Compliance Officers
FDA consulting services are most effective when provided by professionals with direct regulatory inspection experience. Former FDA investigators and compliance officers have conducted inspections of medical device manufacturers and understand how quality systems are evaluated during regulatory inspections. Their experience provides manufacturers with practical insight into inspection procedures, investigator expectations, and common regulatory observations.
Inspection Readiness Advisory Support
Inspection readiness advisory support helps manufacturers strengthen quality system oversight and maintain ongoing readiness for regulatory inspections. FDA consulting services may include review of quality system procedures, CAPA investigations, supplier controls, manufacturing documentation, and postmarket surveillance processes. These activities help organizations evaluate whether their quality systems are properly implemented and supported by adequate documentation.
Preparing Manufacturers for FDA Inspections
Preparing for an FDA inspection requires coordination between quality, regulatory, and operational teams. FDA consulting services and mock FDA inspections help organizations prepare personnel for investigator interviews, document requests, and inspection procedures. By evaluating inspection readiness in advance, manufacturers can address potential compliance risks and improve overall regulatory preparedness.
Reach Out to Our Experts
Contact CIRG FDA Consulting Team
Manufacturers seeking independent FDA consulting support for inspection readiness may contact our team to discuss their regulatory needs. Our consultants include former FDA investigators, compliance officers, and regulatory reviewers with extensive experience inspecting medical device, pharmaceutical, and combination product manufacturers.
We assist organizations preparing for FDA inspections by providing mock FDA inspection services, regulatory guidance, and inspection readiness evaluations aligned with FDA inspection methodology under Compliance Program 7382.850 and current quality management system expectations.
Companies interested in strengthening their inspection readiness, evaluating quality system performance, or preparing personnel for FDA investigator interactions are encouraged to contact our FDA consulting team to discuss available consulting support.